FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...
Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback